Affiliation:
1. Saint Petersburg Research Institute of Ear, Throat, Nose and Speech
Abstract
The problem of long-term and uncontrolled use of decongestants remains one of the most relevant problems of modern otorhinolaryngology. To date vasoconstrictors are the most actively used drugs for the treatment of acute and chronic rhinitis, as well as other diseases accompanied by nasal congestion. Most of the topical decongestants are selective α2-adrenergic agonists that act on postsynaptic α2-adrenergic receptors, which perform the main function in the implementation of sympathetic stimuli in the nasal cavity. Sympathomimetic drugs in addition to the main vasoconstrictor effect also have their own anti-inflammatory and antioxidant effects. Topical decongestants are included in the treatment guidelines for acute and chronic rhinitis, rhinosinusitis, allergic rhinitis, acute and chronic otitis media, eustachitis. The recommended duration of decongestants is usually limited to 5–7 days. Longer use of this drug class can lead to paresis of the nasal mucosa vessels or an allergic reaction, to the development of rhinitis medicamentosa. Side effects that occur with the use of topical decongestants are divided into 2 groups: local symptoms and general toxic reactions. However, with strict adherence to the recommended dosing regimen of topical decongestants, to the method of use and to the duration of use, undesirable side effects are rare. The group of vasoconstrictor drugs received a new development as a result of the combination of decongestants with other drugs, which lead to the reducing local side effects and the elimination of not only nasal congestion, but also other symptoms of the common cold.
Reference28 articles.
1. Klöcker N., Rudolph P., Verse T. Evaluation of protective and therapeutic effects of dexpanthenol on nasal decongestants and preservatives: results of cytotoxic studies in vitro. Am J Rhinol. 2004;18(5):315–320. Available at: https://pubmed.ncbi.nlm.nih.gov/15586804.
2. Lopatin A.S. Nasal Decongestants: Old Drugs and New Formulations. Doktor.Ru = Doctor.Ru. 2011;(6):173–23. (In Russ.) Available at: https://myvrachi.ru/sites/default/files/publications/9429/pdf/nazalnye_dekongestanty_starye_preparaty_i_novye_formy.pdf.
3. Karalskaya Zh., Zryachkin N., Makarova O., Zaitseva G. Topical decongestants in the pediatrician’s practice. Vrach = Doctor. 2010:(8):18–20. (In Russ.) Available at: http://epidem.rusvrach.ru/ru/vrach-2010-08-06.
4. Deckx L., De Sutter A.I., Guo L., Mir N.A., van Driel M.L. Nasal decongestants in monotherapy for the common cold. Cochrane Database Syst Rev. 2016;10(10):CD009612. doi: 10.1002/14651858.CD009612.pub2.
5. Mortuaire G., de Gabory L., François M., Massé G., Bloch F., Brion N. et al. Rebound congestion and rhinitis medicamentosa: nasal decongestants in clinical practice. Critical review of the literature by a medical panel. Eur Ann Otorhinolaryngol Head Neck Dis. 2013;130(3):137–144. doi: 10.1016/j.anorl.2012.09.005.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献